Table 2. Sensitivity (S) and Specificity (Sp) values for the Duplex VL-LFD compared with the commercial assay and with values from other published studies using rK39-based ICTs for diagnosis of human VL in Brazil.
| Assay | % Sensitivity (S, 95% CI) | % Specificity (Sp, 95% CI) | Year of study | Reference |
|---|---|---|---|---|
| DUPLEX VL-LFD* | 90.9 (78.9–100) | 98.7 (96.1–100) | 2019 | This study |
| IT-LEISH®* | 77.3 (59.8–94.8) | 94.7 (89.6–99.8) | 2019 | This study |
| OnSite™ Leishmania IgG/IgM Combo | 91.2 (84.5–95.1) | 94.5 (86.7–97.9) | 2018 | [37] |
| DiaMed-IT LEISH® | 90.0–96.0 | 93.0–100.0 | 2015 | [28] |
| Kalazar Detect™* | 72.4 (64.6–79) | 99.6 (97.6–99.9) | 2013 | [30] |
| Kalazar Detect™* | 46.6 (30.7–62.6) | 97.1 (90.0–99.6) | 2013 | [4] |
| CrystalKA | 61.5 (55.2–67.4) | 98.4 (95.9–99.4) | 2012 | [29] |
| DiaMed-IT LEISH® | 92.0 (87.8–94.8) | 95.6 (92.2–97.5) | ||
| Kalazar Detect™ | 84.7 (79.7–88.7) | 96.8 (93.9–98.4) | ||
| Signal–KA | 79.2 (73.7–83.8) | 98.8 (96.6–99.6) | ||
| Kalazar Detect™ IT-LEISH® |
88.1 (83.0–92.3) 93.3 (89.0–96.4) |
90.6 (82.3–96.0) 96.5 (90.0–99.3) |
2012 | [38] |
| IT-LEISH® | 93 (89.2–96.4) | 97.0 (92.0–99.1) | 2011 | [39] |
| rK39 (TRAld)* | 88.9 | 96.0 | 2009 | [31] |
| DiaMed IT-LEISH® | 93.0 | 97.0 | 2008 | [40] |